Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Healthcare
Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.


TSX:GUD - Post by User

Knight Therapeutics Inc > While other biotech steam forward. DUG looks behind the
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(3)
•••
Comment by porksnifferon Nov 27, 2020 5:02pm
82 Views
Post# 31992735

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:While other biotech steam forward. DUG looks behind the

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:While other biotech steam forward. DUG looks behind the
MrMugsy wrote: The price of PLB at $65 was not a fluke.  The price at double that was.  I’m not buying this one for the lucky benefits during the first go-around.

Not sure why you make these assumptions about me.

You are very angry Porky ... consuming you.




Your gaslighting doesn't do a thing to me. Water of a duck's back. Whomever takes a contrary position to yours is 'angry'. You do the same thing to Benedict too. It's more a reflection of your supreme arrogance. Posters who don't agree with you and your percieved God like status for the CEO are 'angry'. lol... This stock is a turd and you're a big loser here like pretty much every shareholder. This will not be the next Palladin. Read it again. "Better lucky then smart". Let it sink in. 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities